For ACT/TIL – less IL-2 works better. Did I read that right?

› Forums › General Melanoma Community › For ACT/TIL – less IL-2 works better. Did I read that right?

  • Post
    • June 2, 2014 at 4:54 pm
    arthurjedi007
    Participant

      So If I read this right which comes from NCT01468818 the patients who do less IL-2 bags have a better response than the ones who do more bags? At least for this type of treatment. Did I read that right?

      "In our prior clinical trials of cell transfer using TIL after lymphodepletion with or without

      2Gy total body irradiation, patients who experienced an objective response received fewer doses of IL-2 compared to non-responders (p=0.007 and 0.03 respectively)."

    Viewing 2 reply threads
    • Replies
        • June 2, 2014 at 6:59 pm
        BrianP
        Participant

          I had to read it a couple times too but I think that's what they are saying. 

           

          "IL-2 administration has been shown to increase the number of T regulatory cells and in our trials we have found a direct relationship between the number of IL-2 doses and the reconstitution of patients at one week with CD4+ Foxp3+ T regulatory cells.
           
          In our analysis of factors that relate to the ability of this treatment to mediate objective responses, we have found a highly significant inverse correlation between reconstitution of CD4+ Foxp3+ T regulatory cells and the likelihood of achieving an objective response.
           
          In our prior clinical trials of cell transfer using TIL after lymphodepletion with or without 2Gy total body irradiation, patients who experienced an objective response received fewer doses of IL-2 compared to non-responders (p=0.007 and 0.03 respectively).
           
          High levels of the homeostatic T cell growth factor, IL-15, are present in patient serum after the lymphodepleting regimen at the time of cell transfer.
           
          These factors raise the possibility that IL-2 administration is not required after cell transfer."
          • June 2, 2014 at 6:59 pm
          BrianP
          Participant

            I had to read it a couple times too but I think that's what they are saying. 

             

            "IL-2 administration has been shown to increase the number of T regulatory cells and in our trials we have found a direct relationship between the number of IL-2 doses and the reconstitution of patients at one week with CD4+ Foxp3+ T regulatory cells.
             
            In our analysis of factors that relate to the ability of this treatment to mediate objective responses, we have found a highly significant inverse correlation between reconstitution of CD4+ Foxp3+ T regulatory cells and the likelihood of achieving an objective response.
             
            In our prior clinical trials of cell transfer using TIL after lymphodepletion with or without 2Gy total body irradiation, patients who experienced an objective response received fewer doses of IL-2 compared to non-responders (p=0.007 and 0.03 respectively).
             
            High levels of the homeostatic T cell growth factor, IL-15, are present in patient serum after the lymphodepleting regimen at the time of cell transfer.
             
            These factors raise the possibility that IL-2 administration is not required after cell transfer."
            • June 2, 2014 at 6:59 pm
            BrianP
            Participant

              I had to read it a couple times too but I think that's what they are saying. 

               

              "IL-2 administration has been shown to increase the number of T regulatory cells and in our trials we have found a direct relationship between the number of IL-2 doses and the reconstitution of patients at one week with CD4+ Foxp3+ T regulatory cells.
               
              In our analysis of factors that relate to the ability of this treatment to mediate objective responses, we have found a highly significant inverse correlation between reconstitution of CD4+ Foxp3+ T regulatory cells and the likelihood of achieving an objective response.
               
              In our prior clinical trials of cell transfer using TIL after lymphodepletion with or without 2Gy total body irradiation, patients who experienced an objective response received fewer doses of IL-2 compared to non-responders (p=0.007 and 0.03 respectively).
               
              High levels of the homeostatic T cell growth factor, IL-15, are present in patient serum after the lymphodepleting regimen at the time of cell transfer.
               
              These factors raise the possibility that IL-2 administration is not required after cell transfer."
          Viewing 2 reply threads
          • You must be logged in to reply to this topic.
          About the MRF Patient Forum

          The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

          The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

          Popular Topics